Abstract:1155 Objectives Prostate specific membrane antigen (PSMA) is a membrane bound glycoprotein that is overexpressed on the cell surface of prostate cancer cells. A few PSMA-targeting radiotracers have been successfully introduced in clinical studies for imaging prostate cancer by PET. 18F-DCFPyL is currently the most sensitive tracer for the identification of PSMA-positive prostate cancer. However, the procedure for producing 18F-DCFPyL involves multiple synthesis steps. In this study, two 18F-labeled PSMA-targeting tracers (HTK-01069 and HTK-01070) that could be radiolabeled via 18F-19F isotope exchange on the ammoniomethyl-trifluoroborate (AmBF3) motif were synthesized and evaluated for PSMA imaging. Methods HTK-01069 was synthesized by coupling succinimido 4-(N-trifluoroborylmethyl-N,N-dimethylammonio)methylbenzoate to Lys-C(O)-Glu urea. HTK-01070 was prepared by coupling tetrafluorophenyl 4-(azidemethyl)benzoate to t-butyl protected Lys-C(O)-Glu urea, followed by deprotection and click reaction with N-propargyl-N,N-dimethyl-ammoniomethyltrifluoroborate. 18F-19F isotope exchange reactions were conducted for radiolabeling and both tracers were purified by HPLC. The stability of the tracers was assessed in mouse plasma for 2 h and LogD7.4 values were determined by the shake-flask method. PET imaging and biodistribution studies were performed in mice bearing PSMA-expressing LNCap prostate cancer xenografts. For blocking studies, mice were co-injected with 0.5 mg of DCFPyL. Results 18F-HTK-01069 and 18F-HTK-01070 were obtained in 9% and 3% decay-corrected radiochemical yields with > 99% radiochemical purity. The specific activities for 18F-HTK-01069 and 18F-HTK-01070 were 2.0 and 1.3 Ci/μmol, respectively. Both tracers were stable after 2 h incubation in plasma and were highly hydrophilic with LogD7.4 values between -3.4 and -4.3. From the PET and biodistribution data, 18F-HTK-01069 and 18F-HTK-01070 demonstrated clear PSMA-dependent uptake in LNCap prostate cancer xenografts at 1 h post-injection (p.i.). The clearance of both 18F-HTK-01069 and 18F-HTK-01070 was predominantly renal with minor involvement of the hepatobiliary pathway. At 1 h p.i., 18F-HTK-01070 exhibited higher tumour uptake (8.28 ± 1.25 %ID/g) than 18F-HTK-01069 (5.82 ± 1.09 %ID/g). 18F-HTK-01070 was also superior to 18F-HTK-01069 in terms of tumour-to-muscle ratio (37.7 ± 9.53 vs. 18.9 ± 6.05) and tumour-to-blood ratio (16.0 ± 1.37 vs. 11.9 ± 4.60). With PSMA blockade, uptake in tumours decreased significantly to 0.33 ± 0.07 and 0.27 ± 0.06 %ID/g for 18F-HTK-01069 and 18F-HTK-01070, respectively. Conclusions Two novel imaging agents, 18F-HTK-01069 and 18F-HTK-01070, were synthesized and evaluated for targeting PSMA expression with PET. Administration of 18F-HTK-01069 or 18F-HTK-01070 allowed for clear visualization of LNCap tumours in mice, with 18F-HTK-01070 yielding higher uptake and contrast. The data suggests that 18F-AmBF3-PSMA derivatives are promising agents for detecting PSMA-expressing prostate cancers.

Synthesis and positron emission tomography evaluation of 18 F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer.

[Corrigendum] Synthesis and positron emission tomography evaluation of 18F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer

Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [ 18 F]fluorosulfate PET tracers

Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer

Synthesis and Evaluation of F-18-Ambf3-Psma Derivatives As Pet Imaging Agents for Prostate Cancer

Design, Synthesis and Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Aryl [18f]fluorosulfate Pet Tracers

Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile

Synthesis and Preclinical Evaluation of an Al18F Radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA Ligand

A New Ga-68 Glu-Urea-Lys(Ahx)-Hbed-Cc Derivative As An Imaging Agent For Psma.

Preparation of 68Ga-Psma-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression During Prostate Cancer Progression.

Synthesis and Evaluation of a Novel Urea-Based 68Ga-Complex for Imaging PSMA Binding in Tumor.

New 68ga Glu-Urea-Lys(Ahx)-HBED-CC Derivatives As Prostate Specific Membrane Antigen (PSMA) Imaging Agents.

The imaging study of a small-molecular inhibitor targeting prostate speciifc membrane antigen

[(18)F]fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Synthesis of 18F-PSMA-1007 by One-Step Method and PET/CT Imaging in Prostate Cancer

Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging

Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: in Vivo Imaging in Experimental Models of Prostate Cancer.

Preclinical evaluation and first in human study of Al18F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer

Synthesis and Evaluation of Novel Radioiodinated PSMA Targeting Ligands for Potential Radiotherapy of Prostate Cancer.

Design, Preclinical Evaluation, and First-in-human PET Study of [68Ga]ga-Psfa-01: a PSMA/FAP Heterobivalent Tracer

Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging